3.0
Dec 21, 2016
Former employee, more than 1 year
Raleigh, NC
Recommend
CEO approval
Business outlook
Pros
Good friendly R&D colleagues at the RTP site, most of which were let go in 2015. Some "DPUs" were bringing some interesting programs to the pipeline.
Cons
Huge R&D organization with lots of layers, massive bureaucracy, all process driven with zero thinking or creativity, brutal inter-site competition. GSK now knows that it cannot compete as an R&D organization, it's unable to discover and develop new drugs, new CEO coming in 2017 to try to stop downward spiral, good luck.